Published in

Public Library of Science, PLoS ONE, 9(11), p. e0163444, 2016

DOI: 10.1371/journal.pone.0163444

Links

Tools

Export citation

Search in Google Scholar

Multi-center evaluation of the fully automated PCR-based Idylla™ KRAS mutation assay for rapid KRAS mutation status determination on formalin-fixed paraffin-embedded tissue of human colorectal cancer

Journal article published in 2016 by Jerome J. Solassol, Julie J. Vendrell, Bruno B. Märkl ORCID, Christian C. Haas, Beatriz B. Bellosillo, Clara C. Montagut, Fernando F. De Lander Schmitt, Matthew M. Smith, Brendan B. O'Sullivan, Marie Le Mercier, Nicky D'Haene, Morten M. Grauslund, Linea Cecilie L. C. Melchior, Emma E. Burt, Finbarr F. Cotter and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Since the advent of monoclonal antibodies against epidermal growth factor receptor (EGFR) in colorectal cancer therapy, the determination of RAS mutational status is needed for therapeutic decision-making. Most prevalent in colorectal cancer are KRAS exon 2 mutations (40% prevalence); lower prevalence is observed for KRAS exon 3 and 4 mutations (6%) and NRAS exon 2, 3, and 4 mutations (5%). The Idylla™ KRAS Mutation Test on the molecular diagnostics Idylla™ platform is a simple (